Deep Track Capital, LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Deep Track Capital, LP reported 65 stock positions worth $3.5 billion. Its top holding was Springworks Therapeutics (SWTX) at 4.9% of the portfolio, followed by Amgen (AMGN, 4.5%) and Apogee Therapeutics (APGE, 4.4%). Compared with Q4 2023, it opened 19 new positions, sold out of 11, added to 14 and reduced 16. The biggest buy was a new position in Amgen (AMGN) and the biggest sale Insmed (INSM, shares −11%).
- Most Recent 13F
- Q2 2026
- Location
- GREENWICH, CT
- CIK
- 0001856083
- Portfolio Value
- $3.5B (Q1 2024)
- SEC Filing
- 0001856083-24-000002 ↗ filed May 15, 2024
Holdings Value
Holdings 65 stocks · $3.5B
| SWTX Springworks Therapeutics Inc. | 4.92% | 3,479,853 | $171.3M | Reduce -14.4% |
| AMGN Amgen Inc. | 4.49% | 550,000 | $156.4M | New |
| APGE Apogee Therapeutics Inc. | 4.44% | 2,323,456 | $154.4M | No change |
| INSM Insmed Inc. | 3.73% | 4,783,679 | $129.8M | Reduce -10.6% |
| DYN Dyne Therapeutics Inc. | 3.72% | 4,555,383 | $129.3M | Add +127.8% |
| ALNY Alnylam Pharmaceuticals Inc. | 3.58% | 832,310 | $124.4M | New |
| GH Guardant Health Inc. | 3.56% | 6,000,000 | $123.8M | Add +20.0% |
| ARGX Argenx SE - ADR | 3.40% | 300,000 | $118.1M | No change |
| NTLA Intellia Therapeutics Inc. | 3.33% | 4,210,784 | $115.8M | Add +87.2% |
| OCUL Ocular Therapeutix Inc. | 3.33% | 12,721,460 | $115.8M | Add +37.8% |
| DVAX Dynavax Technologies Corp. | 3.26% | 9,141,660 | $113.4M | Add +28.9% |
| AXSM Axsome Therapeutics Inc. | 2.99% | 1,304,721 | $104.1M | Add +30.5% |
| ITCI Intra-Cellular Therapies Inc. | 2.98% | 1,500,000 | $103.8M | Reduce -25.0% |
| GERN Geron Corp. | 2.89% | 30,505,929 | $100.7M | Add +3.1% |
| AUTL Autolus Therapeutics PLC | 2.80% | 15,272,172 | $97.4M | Add +28.7% |
| FDMT 4D Molecular Therapeutics Inc. | 2.78% | 3,034,453 | $96.7M | Add +32.8% |
| ALKS Alkermes PLC | 2.72% | 3,500,000 | $94.7M | Reduce -12.5% |
| BCYC Bicycle Therapeutics PLC-ADR | 2.50% | 3,490,506 | $86.9M | No change |
| PLRX Pliant Therapeutics Inc. | 2.46% | 5,750,000 | $85.7M | No change |
| MIND MEDICINE MINDMED INC | 1.80% | 6,666,667 | $62.7M | New |
| ABVX Abivax SA-ADR | 1.77% | 4,297,438 | $61.5M | No change |
| VRDN Viridian Therapeutics Inc. | 1.74% | 3,456,053 | $60.5M | Reduce -4.8% |
| IONS Ionis Pharmaceuticals Inc. | 1.71% | 1,373,475 | $59.5M | Add +10.0% |
| APLS Apellis Pharmaceuticals Inc. | 1.69% | 1,000,000 | $58.8M | New |
| ANIP Ani Pharmaceuticals Inc. | 1.63% | 822,001 | $56.8M | Add +37.0% |
| TVTX Travere Therapeutics Inc. | 1.63% | 7,370,000 | $56.8M | No change |
| VRNA Verona Pharma Ltd. | 1.47% | 3,187,415 | $51.3M | No change |
| KYMR Kymera Therapeutics Inc. | 1.46% | 1,262,246 | $50.7M | New |
| IVVD Invivyd Inc. | 1.40% | 10,953,937 | $48.6M | New |
| SYRE Spyre Therapeutics Inc. | 1.32% | 1,213,420 | $46.0M | Reduce -37.9% |
| NRIX Nurix Therapeutics Inc. | 1.27% | 2,997,830 | $44.1M | No change |
| HLVX Hillevax Inc. | 1.23% | 2,572,460 | $42.8M | Reduce -11.3% |
| EDIT Editas Medicine Inc. | 1.18% | 5,527,290 | $41.0M | Add +1.0% |
| FATE Fate Therapeutics Inc. | 1.18% | 5,572,607 | $40.9M | New |
| TERN Terns Pharmaceuticals Inc. | 1.15% | 6,100,000 | $40.0M | No change |
| ENGN Engene Holdings Inc. | 1.10% | 2,250,000 | $38.1M | New |
| TRML Tourmaline Bio Inc. | 1.05% | 1,595,400 | $36.5M | Reduce -12.1% |
| OLMA Olema Pharmaceuticals Inc. | 1.05% | 3,225,419 | $36.5M | Add +67.0% |
| SLN Silence Therapeutics PLC-ADR | 1.02% | 1,643,881 | $35.5M | Reduce -15.8% |
| PACB Pacific Biosciences of Calif | 0.75% | 7,000,000 | $26.3M | No change |
| CYBIN INC | 0.69% | 58,139,535 | $24.0M | New |
| ALEC Alector Inc. | 0.65% | 3,769,386 | $22.7M | New |
| NUVL Nuvalent Inc. Class A | 0.59% | 274,512 | $20.6M | Reduce -39.0% |
| AGEN Agenus Inc. | 0.53% | 31,697,539 | $18.4M | No change |
| PYXS Pyxis Oncology Inc. | 0.51% | 4,184,100 | $17.8M | New |
| NKTR Nektar Therapeutics | 0.49% | 18,400,000 | $17.2M | No change |
| IMVT Immunovant Inc. | 0.46% | 493,352 | $15.9M | Reduce -50.7% |
| NMRA Neumora Therapeutics Inc. | 0.40% | 1,000,000 | $13.8M | New |
| RPTX Repare Therapeutics Inc. | 0.36% | 2,684,344 | $12.6M | Reduce -10.3% |
| SRRK Scholar Rock Holding Corp. | 0.35% | 680,000 | $12.1M | Reduce -32.8% |
| ANAB Anaptysbio Inc. | 0.34% | 529,452 | $11.9M | Reduce -74.0% |
| RGLS Regulus Therapeutics Inc. | 0.27% | 3,266,566 | $9.4M | New |
| ANRO Alto Neuroscience Inc. | 0.26% | 600,000 | $9.2M | New |
| RARE Ultragenyx Pharmaceutical Inc. | 0.23% | 167,784 | $7.8M | New |
| ZURA Zura Bio Ltd. | 0.19% | 2,523,000 | $6.5M | No change |
| ALLK Allakos LLC | 0.18% | 5,000,000 | $6.3M | Add +99.1% |
| ALGS Aligos Therapeutics Inc. | 0.17% | 6,102,770 | $6.0M | No change |
| RLMD Relmada Therapeutics Inc. | 0.17% | 1,240,034 | $5.8M | Reduce -39.4% |
| VIGL Vigil Neuroscience Inc. | 0.16% | 1,594,931 | $5.4M | No change |
| MGX Metagenomi Therapeutics Inc. | 0.14% | 466,232 | $4.9M | New |
| SYRS Syros Pharmaceuticals Inc. | 0.13% | 828,485 | $4.4M | No change |
| MERSANA THERAPEUTICS INC | 0.07% | 579,674 | $2.6M | New |
| PRME Prime Medicine Inc. | 0.06% | 303,716 | $2.1M | New |
| COGT Cogent Biosciences Inc. | 0.06% | 316,000 | $2.1M | New |
| GPCR Structure Therapeutics Inc. | 0.05% | 40,137 | $1.7M | Reduce -86.6% |
Options reported separately and not counted above: ITCI puts ($12.1M).
Portfolio Sells Q4 2023 → Q1 2024
| INSM Insmed Inc. | Reduce -10.6% | 3.73% | −2.08 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -25.0% | 2.98% | −2.03 |
| AMAM New Ambrx Biopharma Inc. | Sold out | 0.00% | −1.85 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −1.69 |
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −1.56 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −1.41 |
| ANAB Anaptysbio Inc. | Reduce -74.0% | 0.34% | −1.19 |
| ORTX Orchard Therapeutics Ltd. | Sold out | 0.00% | −1.18 |
| ALKS Alkermes PLC | Reduce -12.5% | 2.72% | −1.16 |
| VRDN Viridian Therapeutics Inc. | Reduce -4.8% | 1.74% | −1.03 |
| IMVT Immunovant Inc. | Reduce -50.7% | 0.46% | −1.02 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −0.97 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.85 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.83 |
| TRML Tourmaline Bio Inc. | Reduce -12.1% | 1.05% | −0.62 |
| NUVL Nuvalent Inc. Class A | Reduce -39.0% | 0.59% | −0.57 |
| RPTX Repare Therapeutics Inc. | Reduce -10.3% | 0.36% | −0.40 |
| HLVX Hillevax Inc. | Reduce -11.3% | 1.23% | −0.40 |
| GPCR Structure Therapeutics Inc. | Reduce -86.6% | 0.05% | −0.38 |
| SRRK Scholar Rock Holding Corp. | Reduce -32.8% | 0.35% | −0.32 |
| SWTX Springworks Therapeutics Inc. | Reduce -14.4% | 4.92% | −0.27 |
| PTGX Protagonist Therapeutics Inc. | Sold out | 0.00% | −0.22 |
| JAZZ Jazz Pharmaceuticals PLC | Sold out | 0.00% | −0.21 |
| SLN Silence Therapeutics PLC-ADR | Reduce -15.8% | 1.02% | −0.17 |
| SYRE Spyre Therapeutics Inc. | Reduce -37.9% | 1.32% | −0.15 |
| RLMD Relmada Therapeutics Inc. | Reduce -39.4% | 0.17% | −0.13 |
| GHRS GH Research PLC | Sold out | 0.00% | −0.10 |
Portfolio Buys Q4 2023 → Q1 2024
| AMGN Amgen Inc. | New | 4.49% | +4.49 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 3.58% | +3.58 |
| DYN Dyne Therapeutics Inc. | Add +127.8% | 3.72% | +2.79 |
| OCUL Ocular Therapeutix Inc. | Add +37.8% | 3.33% | +1.89 |
| MIND MEDICINE MINDMED INC | New | 1.80% | +1.80 |
| APLS Apellis Pharmaceuticals Inc. | New | 1.69% | +1.69 |
| KYMR Kymera Therapeutics Inc. | New | 1.46% | +1.46 |
| IVVD Invivyd Inc. | New | 1.40% | +1.40 |
| FATE Fate Therapeutics Inc. | New | 1.18% | +1.18 |
| FDMT 4D Molecular Therapeutics Inc. | Add +32.8% | 2.78% | +1.16 |
| ENGN Engene Holdings Inc. | New | 1.10% | +1.10 |
| NTLA Intellia Therapeutics Inc. | Add +87.2% | 3.33% | +0.93 |
| GERN Geron Corp. | Add +3.1% | 2.89% | +0.71 |
| CYBIN INC | New | 0.69% | +0.69 |
| ALEC Alector Inc. | New | 0.65% | +0.65 |
| PYXS Pyxis Oncology Inc. | New | 0.51% | +0.51 |
| ANIP Ani Pharmaceuticals Inc. | Add +37.0% | 1.63% | +0.47 |
| NMRA Neumora Therapeutics Inc. | New | 0.40% | +0.40 |
| RGLS Regulus Therapeutics Inc. | New | 0.27% | +0.27 |
| ANRO Alto Neuroscience Inc. | New | 0.26% | +0.26 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 0.23% | +0.23 |
| AXSM Axsome Therapeutics Inc. | Add +30.5% | 2.99% | +0.20 |
| MGX Metagenomi Therapeutics Inc. | New | 0.14% | +0.14 |
| AUTL Autolus Therapeutics PLC | Add +28.7% | 2.80% | +0.12 |
| OLMA Olema Pharmaceuticals Inc. | Add +67.0% | 1.05% | +0.10 |
| MERSANA THERAPEUTICS INC | New | 0.07% | +0.07 |
| PRME Prime Medicine Inc. | New | 0.06% | +0.06 |
| COGT Cogent Biosciences Inc. | New | 0.06% | +0.06 |
| ALLK Allakos LLC | Add +99.1% | 0.18% | −0.06 |
| DVAX Dynavax Technologies Corp. | Add +28.9% | 3.26% | −0.21 |
| IONS Ionis Pharmaceuticals Inc. | Add +10.0% | 1.71% | −0.50 |
| EDIT Editas Medicine Inc. | Add +1.0% | 1.18% | −0.76 |
| GH Guardant Health Inc. | Add +20.0% | 3.56% | −1.18 |
Options Activity Q4 2023 → Q1 2024
| CYTK Cytokinetics Inc. | call | Sold out | 1,347,300 | $112.5Mbefore exit |
| PRTA Prothena Corp. PLC | call | Sold out | 500,000 | $18.2Mbefore exit |
| ITCI Intra-Cellular Therapies Inc. | put | New | 175,400 | $12.1M |
| PRTA Prothena Corp. PLC | put | Sold out | 250,000 | $9.1Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 66 | $6.8B | GH, IMVT, GPCR, PCVX, ALNY |
| Q1 2026 | 62 | $4.8B | GH, IMVT, TARS, PCVX, GPCR |
| Q4 2025 | 53 | $4.4B | IMVT, GH, GPCR, TARS, DVAX |
| Q3 2025 | 56 | $3.6B | GH, IONS, CYTK, AKRO, APLS |
| Q2 2025 | 65 | $3.1B | GH, IONS, PTGX, DVAX, INSM |
| Q1 2025 | 69 | $3.1B | ITCI, GH, DVAX, IMVT, PTGX |
| Q4 2024 | 61 | $2.7B | DVAX, GH, ITCI, IMVT, APLS |
| Q3 2024 | 69 | $3.1B | ARGX, DVAX, GH, APLS, IMVT |
| Q2 2024 | 67 | $3.3B | AMGN, ARGX, AXSM, DYN, SWTX |
| Q1 2024 | 65 | $3.5B | SWTX, AMGN, APGE, INSM, DYN |